Modeling the Economic Impact of Substandard and Falsified Antimalarials in the Democratic Republic of the Congo

Ozawa, Sachiko; Haynie, Deson G.; Bessias, Sophia; Laing, Sarah K.; Ngamasana, Emery Ladi; Yemeke, Tatenda T.; & Evans, Daniel R. (2019). Modeling the Economic Impact of Substandard and Falsified Antimalarials in the Democratic Republic of the Congo. American Journal of Tropical Medicine and Hygiene, 100(5), 1149-57. PMCID: PMC6493946

Ozawa, Sachiko; Haynie, Deson G.; Bessias, Sophia; Laing, Sarah K.; Ngamasana, Emery Ladi; Yemeke, Tatenda T.; & Evans, Daniel R. (2019). Modeling the Economic Impact of Substandard and Falsified Antimalarials in the Democratic Republic of the Congo. American Journal of Tropical Medicine and Hygiene, 100(5), 1149-57. PMCID: PMC6493946

Octet Stream icon 11797.ris — Octet Stream, 2 kB (2,223 bytes)

Substandard and falsified medicines pose significant risks to global health, including increased deaths, prolonged treatments, and growing drug resistance. Antimalarials are one of the most common medications to be of poor quality in low- and middle-income countries. We assessed the health and economic impact of substandard and falsified antimalarials for children less than 5 years of age in the Democratic Republic of the Congo, which has one of the world's highest malaria mortality. We developed an agent-based model using NetLogo software to model patient care-seeking behavior and medicine supply chain processes to examine the impact of antimalarial quality in Kinshasa Province and Katanga region. We simulated the impact of potential interventions to improve medicinal quality, reduce stock outs, or educate caregivers. We estimated that substandard and falsified antimalarials are responsible for $20.9 million of $59.6 million (95% CI: $20.7-$21.2 million; 35%) in malaria costs in Kinshasa Province and $130 million of $301 million (95% CI: $129-$131 million; 43%) in malaria costs in the Katanga region annually. If drug resistance to artemisinin were to develop, total annual costs of malaria could increase by $17.9 million (95% CI: $17.7-$18.0 million; 30%) and $73 million (95% CI: $72.2-$72.8 million; 24%) in Kinshasa and Katanga, respectively. Replacing substandard and falsified antimalarials with good quality ones had a larger impact than interventions which prevented stock outs or educated caregivers. The results highlight the importance of improving access to good quality antimalarials to reduce the burden of malaria and mitigate the development of antimalarial resistance.




JOUR



Ozawa, Sachiko
Haynie, Deson G.
Bessias, Sophia
Laing, Sarah K.
Ngamasana, Emery Ladi
Yemeke, Tatenda T.
Evans, Daniel R.



2019

P2C-No. No funding info.

American Journal of Tropical Medicine and Hygiene

100

5

1149-57








PMC6493946


11797

Wink Plone Theme by Quintagroup © 2013.

Personal tools
This is themeComment for Wink theme